HUE068183T2 - RPGR génterápia a retinitis pigmentosa terápiájára - Google Patents

RPGR génterápia a retinitis pigmentosa terápiájára

Info

Publication number
HUE068183T2
HUE068183T2 HUE20199208A HUE20199208A HUE068183T2 HU E068183 T2 HUE068183 T2 HU E068183T2 HU E20199208 A HUE20199208 A HU E20199208A HU E20199208 A HUE20199208 A HU E20199208A HU E068183 T2 HUE068183 T2 HU E068183T2
Authority
HU
Hungary
Prior art keywords
gene therapy
retinitis pigmentosa
rpgr gene
rpgr
pigmentosa
Prior art date
Application number
HUE20199208A
Other languages
English (en)
Hungarian (hu)
Inventor
Michael A Sandberg
Basil Pawlyk
Tiansen Li
Xinhua Shu
Alan Finlay Wright
Robin Ali
Original Assignee
Massachusetts Eye & Ear Infirmary
Ucl Business Ltd
The Government Of The Us Secretary Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary, Ucl Business Ltd, The Government Of The Us Secretary Department Of Health And Human Services filed Critical Massachusetts Eye & Ear Infirmary
Publication of HUE068183T2 publication Critical patent/HUE068183T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
HUE20199208A 2014-07-24 2015-07-17 RPGR génterápia a retinitis pigmentosa terápiájára HUE068183T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028638P 2014-07-24 2014-07-24

Publications (1)

Publication Number Publication Date
HUE068183T2 true HUE068183T2 (hu) 2024-12-28

Family

ID=55163577

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE20199208A HUE068183T2 (hu) 2014-07-24 2015-07-17 RPGR génterápia a retinitis pigmentosa terápiájára
HUE15825383A HUE052781T2 (hu) 2014-07-24 2015-07-17 RPGR génterápia a retinitis pigmentosa terápiájára

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15825383A HUE052781T2 (hu) 2014-07-24 2015-07-17 RPGR génterápia a retinitis pigmentosa terápiájára

Country Status (18)

Country Link
US (2) US10314924B2 (enExample)
EP (2) EP3191139B1 (enExample)
JP (3) JP6654760B2 (enExample)
CN (1) CN107206105A (enExample)
CA (1) CA2991750C (enExample)
CY (1) CY1123793T1 (enExample)
DK (2) DK3821912T3 (enExample)
ES (2) ES2987090T3 (enExample)
FI (1) FI3821912T3 (enExample)
HR (2) HRP20202023T1 (enExample)
HU (2) HUE068183T2 (enExample)
LT (2) LT3821912T (enExample)
PL (2) PL3821912T3 (enExample)
PT (2) PT3821912T (enExample)
RS (2) RS65909B1 (enExample)
SI (2) SI3191139T1 (enExample)
SM (2) SMT202400309T1 (enExample)
WO (1) WO2016014353A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400309T1 (it) * 2014-07-24 2024-11-15 Massachusetts Eye & Ear Infirmary Terapia genica rpgr per la retinite pigmentosa
WO2016098078A2 (en) * 2014-12-19 2016-06-23 Novartis Ag Dimerization switches and uses thereof
AU2016228751B2 (en) 2015-03-11 2022-01-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
GB201704192D0 (en) 2017-03-16 2017-05-03 Nightstarx Ltd Treatment of Retinitis Pigmentosa
WO2019077159A1 (en) * 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR
MY204271A (en) * 2017-11-15 2024-08-20 Ucl Business Ltd Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
IL296262A (en) * 2020-03-11 2022-11-01 Massachusetts Eye & Ear Infirmary Gene therapy for nmnat1-related retinal degeneration
CN120350069A (zh) * 2024-01-12 2025-07-22 北京中因科技有限公司 视网膜色素变性动物模型及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
EP0633318A1 (en) 1987-09-11 1995-01-11 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
HK1008400A1 (en) 1987-12-11 1999-05-07 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
ATE152169T1 (de) 1988-02-05 1997-05-15 Whitehead Biomedical Inst Modifizierte hepatozyten und deren anwendung
ATE147102T1 (de) 1990-10-31 1997-01-15 Somatix Therapy Corp Nützliche retrovirale vektoren für die gentherapie
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
AU2044901A (en) 1999-11-24 2001-06-04 Cornell Research Foundation Inc. Inherited retinal diseases at the canine rp3 locus: linkage, marker- and mutation-based tests
GB0008801D0 (en) 2000-04-10 2000-05-31 Medical Res Council Sequences
CN102925445A (zh) * 2011-08-08 2013-02-13 刘军 一种获得rpgr 基因新的转录剪切形式的方法
AU2013287281B2 (en) * 2012-07-11 2018-04-26 The Trustees Of The University Of Pennsylvania AAV-mediated gene therapy for RPGR x-linked retinal degeneration
GB201412011D0 (en) * 2014-07-04 2014-08-20 Ucl Business Plc Treatments
SMT202400309T1 (it) * 2014-07-24 2024-11-15 Massachusetts Eye & Ear Infirmary Terapia genica rpgr per la retinite pigmentosa

Also Published As

Publication number Publication date
JP2020073536A (ja) 2020-05-14
LT3191139T (lt) 2021-01-25
ES2834402T3 (es) 2021-06-17
HRP20241154T1 (hr) 2024-11-22
JP6654760B2 (ja) 2020-02-26
DK3191139T3 (da) 2020-11-16
RS65909B1 (sr) 2024-10-31
EP3191139B1 (en) 2020-10-07
EP3821912A1 (en) 2021-05-19
FI3821912T3 (fi) 2024-08-05
EP3191139A4 (en) 2018-01-10
SI3191139T1 (sl) 2021-03-31
PL3191139T3 (pl) 2021-07-05
PT3821912T (pt) 2024-08-01
JP2022009333A (ja) 2022-01-14
JP6966532B2 (ja) 2021-11-17
US20200215203A1 (en) 2020-07-09
JP2017523239A (ja) 2017-08-17
JP7198329B2 (ja) 2022-12-28
ES2987090T3 (es) 2024-11-13
US10314924B2 (en) 2019-06-11
LT3821912T (lt) 2024-09-25
HRP20202023T1 (hr) 2021-03-05
US20170216454A1 (en) 2017-08-03
SMT202400309T1 (it) 2024-11-15
SI3821912T1 (sl) 2024-10-30
RS61307B1 (sr) 2021-02-26
EP3191139A1 (en) 2017-07-19
CN107206105A (zh) 2017-09-26
CY1123793T1 (el) 2022-05-27
PL3821912T3 (pl) 2024-10-28
PT3191139T (pt) 2020-11-05
EP3821912B1 (en) 2024-06-12
SMT202000715T1 (it) 2021-01-05
US11045558B2 (en) 2021-06-29
WO2016014353A1 (en) 2016-01-28
DK3821912T3 (da) 2024-08-05
HUE052781T2 (hu) 2021-05-28
CA2991750A1 (en) 2016-01-28
CA2991750C (en) 2023-02-14

Similar Documents

Publication Publication Date Title
IL284741B (en) Gene therapy for retinitis pigmentosa
IL304084B1 (en) Gene healing
GB201420139D0 (en) Factor IX gene therapy
SMT202000715T1 (it) Terapia genica rpgr per la retinite pigmentosa
GB201407322D0 (en) Gene therapy
GB201707212D0 (en) Gene therapy for ciliopathies
GB201701968D0 (en) Gene therapy
GB201513151D0 (en) Functional gene replacement therapy
GB201616821D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
GB201704634D0 (en) Gene therapy
SG10201912076UA (en) Gene therapy composition
GB201410595D0 (en) Factor IX gene therapy